IMMUNOTHERAPY EFFICACY TARGETING ENDOMETRIAL CANCER

DMMR Cancer, Endometrial Carcinoma (EC), pMMR

Endometrial carcinoma (EC) represents the most common gynecological malignancy in developed countries. Despite therapeutic advances, patients with advanced or recurrent disease still have a poor prognosis, with high recurrence rates and a 5-year survival of less than 20%. Recently, four phase III studies (RUBY, NRG-GY018, AtTEnd, and DUO-E) have demonstrated that the addition of anti-PD-1/PD-L1 immunotherapy to first-line chemotherapy significantly improves progression-free survival, particularly in tumors with altered DNA repair mechanisms known as mismatch repair (MMR) (so-called mismatch repair-deficient or dMMR tumors), but with benefits also observed in a subset of tumors with normal MMR function (so-called MMR-proficient or pMMR tumors). However, despite the clinical approval of these therapies, reliable biomarkers capable of predicting response to immunotherapy are still lacking. This project aims to comprehensively characterize the genomic, epigenetic, and lipid properties of the tumor and the tumor microenvironment (TME) in order to identify predictive markers of response to immunotherapy, thereby laying the foundation for a personalized therapeutic approach in endometrial carcinoma.

Primary objective To identify and validate predictive biomarkers of response to immunotherapy in dMMR and pMMR endometrial carcinomas through an integrated multi-omics approach (genomic, epigenomic, transcriptomic, and lipidomic) and functional validation in patient-derived models. Population characteristics Patients with advanced (stage III-IV) or recurrent epithelial endometrial carcinoma, treated with anti-PD-1/PD-L1 immunotherapy in combination with or following standard platinum-based chemotherapy at the European Institute of Oncology. Inclusion criteria: Advanced or recurrent endometrial carcinoma patients undergoing biopsy or cytoreductive surgery followed by immunotherapy Age ≥ 18 years Fresh tumor tissue available at the IEO Biobank Written informed consent Exclusion criteria: Mesenchymal tumors Carcinomas of non-endometrial origin Chronic viral infections (HIV, HBV, HCV) Number of patients and main criteria * Total number of planned patients: 50 * Number of IEO patients: 50 * Competitive: No * Special population: Rare disease / advanced tumor * Sex and menopausal status: Female, pre- or post-menopausal * Disease stage: III-IV (advanced or recurrent) * Main subtypes: dMMR and pMMR; molecular subgroups (POLE, p53, NSMP) when available Duration (in months) * Enrollment duration: 18 * Follow-up duration: 12 (calculated from the last patient enrolled) Rationale: with approximately 150 new EC cases per year at IEO (about 20% advanced/recurrent), enrolling 50 patients over 18 months is realistic; a 12-month follow-up allows for clinical evaluations (response/early PFS) that are useful for multi-omics analyses and validation.

No related papers found yet.

Italy